XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis-Reference-Cited by-同舟云学术

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

Published:2012-06-29 Issue:1 Volume:12 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Pectasides Dimitrios,Papaxoinis George,Kalogeras Konstantine T,Eleftheraki Anastasia G,Xanthakis Ioannis,Makatsoris Thomas,Samantas Epaminondas,Varthalitis Ioannis,Papakostas Pavlos,Nikitas Nikitas,Papandreou Christos N,Pentheroudakis George,Timotheadou Eleni,Koutras Angelos,Sgouros Joseph,Bafaloukos Dimitrios,Klouvas George,Economopoulos Theofanis,Syrigos Konstantinos N,Fountzilas George

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/1471-2407-12-271.pdf

Reference27 articles.

1. Fuchs CS, Marshall J, Barrueco J: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol. 2008, 26: 689-690. 10.1200/JCO.2007.15.5390.

2. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007, 25: 4779-4786. 10.1200/JCO.2007.11.3357.

3. Pritchard CC, Grady WM: Colorectal cancer molecular biology moves into clinical practice. Gut. 2011, 60: 116-129. 10.1136/gut.2009.206250.

4. Köhne CH, De Greve J, Hartmann JT Lang I, Vergauwe P, Becker K, Braumann D, Joosens E, Müller L, Janssens J, Bokemeyer C, Reimer P, Link H, Späth-Schwalbe E, Wilke HJ, Bleiberg H, Van Den Brande J, Debois M, Bethe U, Van Cutsem E: Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol. 2008, 19: 920-926. 10.1093/annonc/mdm544.

5. García-Alfonso P, Muñoz-Martin AJ, Alvarez-Suarez S, Jerez-Gilarranz Y, Riesco-Martinez M, Khosravi P, Martin M: Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer. Br J Cancer. 2010, 103: 1524-1528. 10.1038/sj.bjc.6605907.

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC;Med;2024-09

2. Overall survival with non-proportional hazards in first-line treatment for patients with metastatic colorectal cancer: Systematic review and network meta-analysis;Heliyon;2024-08

3. Safety of first-line systemic therapy in patients with metastatic colorectal cancer: a network meta-analysis of randomized controlled trials;BMC Cancer;2024-07-24

4. Systemic Therapy for Metastatic Colon Cancer: New Frontiers;Clinics in Colon and Rectal Surgery;2024-06-25

5. A phase I/II study of nintedanib and capecitabine for refractory metastatic colorectal cancer;JNCI Cancer Spectrum;2024-04-30